Needham Reiterates Buy on BioCryst Pharma, Maintains $16 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.9%

Neg 0% Neu 87.9% Pos 0%

Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $16 price target.

Comments

No comments yet. Be the first!